
## Marta Tellez-Gabriel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2823558/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Liquid biopsy in bone sarcomas and identification of new biomarkers. , 2022, , 487-500.		0
2	Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity. Theranostics, 2019, 9, 4580-4594.	10.0	69
3	The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelialâ€like head and neck carcinoma subtypes. Head and Neck, 2019, 41, 1830-1845.	2.0	9
4	Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine. Cancers, 2019, 11, 19.	3.7	48
5	Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality?. Drug Discovery Today, 2019, 24, 763-772.	6.4	46
6	Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy. Journal of Bone Oncology, 2018, 12, 83-90.	2.4	20
7	Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip. European Journal of Cell Biology, 2017, 96, 110-118.	3.6	11
8	Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma. Journal of Translational Medicine, 2017, 15, 115.	4.4	16
9	Cancer stem cells in osteosarcoma. Cancer Letters, 2017, 386, 189-195.	7.2	224
10	Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis. International Journal of Molecular Sciences, 2016, 17, 2142.	4.1	129
11	The Challenges of Detecting Circulating Tumor Cells in Sarcoma. Frontiers in Oncology, 2016, 6, 202.	2.8	21
12	CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advancedâ€stage head and neck squamous cell carcinoma. Head and Neck, 2016, 38, E1392-403.	2.0	16
13	ΔNp63α Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFÎ2-Induced Metastasis. Cancer Research, 2016, 76, 3236-3251.	0.9	48
14	Circulating Tumor Cells: A Review of Non–EpCAM-Based Approaches for Cell Enrichment and Isolation. Clinical Chemistry, 2016, 62, 571-581.	3.2	196
15	Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. Journal of Bone Oncology, 2015, 4, 1-12.	2.4	116